3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Pheochromocytoma
1
Paraganglioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Meningioma
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
lutetium Lu 177 dotatate
3
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
zimberelimab
1
pasireotide
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Somatostatin
1
Radiosurgery
1
Everolimus
1
Disulfides
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled